<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05120037</url>
  </required_header>
  <id_info>
    <org_study_id>STU00215708</org_study_id>
    <nct_id>NCT05120037</nct_id>
  </id_info>
  <brief_title>MRI Study of High Definition Transcranial Electrical Stimulation in Chronic Tinnitus (MRI HDtES-T)</brief_title>
  <acronym>MRI HDtES-T</acronym>
  <official_title>MRI Study of High Definition Transcranial Electrical Stimulation in Chronic Tinnitus (MRI HDtES-T)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to understand how a neurostimulation technique, transcranial&#xD;
      electrical stimulation (tES), affects brain function in adults with chronic subjective&#xD;
      tinnitus measured with functional magnetic resonance imaging (fMRI). This study targets a&#xD;
      specific kind of tES called transcranial direct current stimulation (tDCS), where a mild,&#xD;
      constant current is passed between electrodes placed on the scalp.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an investigator-initiated MRI study of High Definition (HD) transcranial electrical&#xD;
      stimulation (tES) in adults with chronic subjective tinnitus. HDtES is a mild, noninvasive&#xD;
      form of brain stimulation using small electrodes to target a small part of the brain/cortex.&#xD;
      Primary outcomes are changes in brain function and connectivity measured with MRI before and&#xD;
      after a single 20-minute session of HDtES. Secondary outcomes are changes in tinnitus&#xD;
      symptoms after 20-minutes of HDtES on 5 consecutive days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in brain functional connectivity.</measure>
    <time_frame>immediate</time_frame>
    <description>Functional MRI will measure changes in brain function during tDCS. Specifically, the investigators will measure change in functional connectivity of prefrontal cortex (% change in Fisher's z).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in tinnitus symptoms</measure>
    <time_frame>1 week, 2 weeks, 1 month</time_frame>
    <description>Symptoms of tinnitus will be measured before and after 5 sessions of tDCS using the Tinnitus Functional Index (TFI). Change in TFI scores will be used as a secondary outcome measure. Score range is 0-100, where low scores indicate low symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Tinnitus, Subjective</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial Direct Current Stimulation</intervention_name>
    <description>Transcranial Direct Current Stimulation (tDCS) uses a mild electrical current to make small (or subtle) changes to how the brain works (or functions).</description>
    <arm_group_label>Active</arm_group_label>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ages between 18 and 75&#xD;
&#xD;
          2. Race/ethnicity: all races and ethnic groups&#xD;
&#xD;
          3. Sex/Gender: all&#xD;
&#xD;
          4. Capacity to provide informed consent&#xD;
&#xD;
          5. Subjective tinnitus symptoms confirmed by patient self report meeting the following&#xD;
             criteria:&#xD;
&#xD;
               1. Present for at least one year prior to start of study&#xD;
&#xD;
               2. Present (can be heard when consciously attended to) &gt;50% of awake time&#xD;
&#xD;
               3. Intrudes (is heard even when attempting to ignore/mask) &gt;10% of awake time&#xD;
&#xD;
          6. Has discussed tinnitus symptoms with clinician (i.e., physician, audiologist) to&#xD;
             confirm low/no likelihood of physical or neurological origin of tinnitus symptoms&#xD;
             (e.g., acoustic neuroma, Meniere's Disease, etc.), confirmed by patient self-report&#xD;
&#xD;
          7. Stable standard or no pharmacological treatment regimen for tinnitus with no change in&#xD;
             treatment 6 weeks prior to study start&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Ages below 18 (neurobiology is quite different in children vs. adults)&#xD;
&#xD;
          2. Ages above 75 (cortical excitability changes with age)&#xD;
&#xD;
          3. Tinnitus symptoms with known medial origin, including:&#xD;
&#xD;
               1. Meniere's disease&#xD;
&#xD;
               2. Pulsatile tinnitus&#xD;
&#xD;
               3. Acoustic neuroma&#xD;
&#xD;
               4. Spontaneous optoacoustic emissions&#xD;
&#xD;
               5. Any other known medical origin&#xD;
&#xD;
          4. Severe mood disorder (major depression or anxiety)&#xD;
&#xD;
          5. Diagnosis of any medical condition potentially affecting brain function, including:&#xD;
&#xD;
               1. neuropsychiatric or mental disorders (bipolar, post-traumatic stress disorder,&#xD;
                  etc.)&#xD;
&#xD;
               2. severe mood disorders (major depression or anxiety)&#xD;
&#xD;
               3. psychotic states or disorders&#xD;
&#xD;
               4. developmental disorders&#xD;
&#xD;
               5. neurological disorders, including mild cognitive impairment&#xD;
&#xD;
               6. significant head injury&#xD;
&#xD;
               7. significant history of alcohol/substance abuse or dependence&#xD;
&#xD;
               8. active chronic pain condition (&gt;1 year duration)&#xD;
&#xD;
               9. other major medical conditions (e.g., cancer, stroke).&#xD;
&#xD;
          6. MRI contraindications:&#xD;
&#xD;
               1. metal or other implants that are not MR-safe&#xD;
&#xD;
               2. claustrophobia&#xD;
&#xD;
               3. pregnancy or suspected pregnancy&#xD;
&#xD;
          7. tDCS contraindications*:&#xD;
&#xD;
               1. skin conditions or injuries on the scalp&#xD;
&#xD;
               2. hair extensions, wigs, braids, etc. that cannot be removed prior to the study&#xD;
&#xD;
               3. metal implants or pacemakers (also contraindicated for MRI)&#xD;
&#xD;
          8. Non-English speakers (due to written consent and questionnaires administered)&#xD;
&#xD;
          9. Significant history of alcohol/substance abuse or dependence within last 12 months&#xD;
&#xD;
         10. Neurostimulation or neuromodulation treatment longer than 20 minutes within the past 3&#xD;
             months&#xD;
&#xD;
         11. Current medication use potentially affecting brain function, including decongestants,&#xD;
             antihistamines, benzodiazepines or other anticonvulsants, or anti-psychotics.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 12, 2021</study_first_submitted>
  <study_first_submitted_qc>November 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Amber Leaver</investigator_full_name>
    <investigator_title>Research Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinnitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

